grantGrants.gov

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

Organization National Institutes of HealthPosted 18 Nov 2024Deadline 7 Jan 2027
HHS-NIH1193.393synopsis
Sign up free to applyFree account · Full description · Apply link · All opportunity types

Full Description

Opportunity Number: PAR-25-069 Document Type: synopsis CFDA Numbers: 93.393

Read the full description

Sign up freeFree account · No credit card required
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) — National Institutes of Health | Dev Procure